Cargando…

Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2

Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is responsible for the novel coronavirus disease 2019 (COVID-19). An appealing antiviral drug target is the coronavirus 3C-like protease (3CLpro) that is responsible for the processing of the viral polyproteins and liberation of functional...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreira, Juliana C., Rabeh, Wael M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747600/ https://www.ncbi.nlm.nih.gov/pubmed/33335206 http://dx.doi.org/10.1038/s41598-020-79357-0

Ejemplares similares

Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus
por: Hartini, Yustina, et al.
Publicado: (2021)

pH profiles of 3-chymotrypsin-like protease (3CLpro) from SARS-CoV-2 elucidate its catalytic mechanism and a histidine residue critical for activity
por: Al Adem, Kenana, et al.
Publicado: (2022)

Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2
por: Ferreira, Juliana C., et al.
Publicado: (2022)

Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-Chymotrypsin-Like Protease
por: Ferreira, Juliana C., et al.
Publicado: (2021)

Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS‐CoV‐2 protease 3CLpro
por: Ferreira, Juliana C., et al.
Publicado: (2021)

Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
por: Mody, Vicky, et al.
Publicado: (2021)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
por: Kuang, Yi, et al.
Publicado: (2023)

Computer-Aided Screening for Potential Coronavirus 3-Chymotrypsin-like Protease (3CLpro) Inhibitory Peptides from Putative Hemp Seed Trypsinized Peptidome
por: Prasertsuk, Kansate, et al.
Publicado: (2022)

In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2
por: Abdizadeh, Rahman, et al.
Publicado: (2021)

A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors
por: Jo, Seri, et al.
Publicado: (2022)

The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
por: Belenkaya, Svetlana V., et al.
Publicado: (2023)

Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach
por: Molavi, Zahra, et al.
Publicado: (2021)

Synthesis, anti-bacterial evaluation, DFT study and molecular docking as a potential 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2 inhibitors of a novel Schiff bases
por: Al-Janabi, Ahmed S.M., et al.
Publicado: (2021)

Corrigendum: The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
por: Belenkaya, Svetlana V., et al.
Publicado: (2023)

Pharmacoinformatic study of inhibitory potentials of selected flavonoids against papain-like protease and 3-chymotrypsin-like protease of SARS-CoV-2
por: Tijjani, Habibu, et al.
Publicado: (2022)

Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L
por: Costanzi, Elisa, et al.
Publicado: (2021)

A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

Response of Midgut Trypsin- and Chymotrypsin-Like Proteases of Helicoverpa armigera Larvae Upon Feeding With Peanut BBI: Biochemical and Biophysical Characterization of PnBBI
por: Lokya, Vadthya, et al.
Publicado: (2020)

Ginkgolic acid and anacardic acid are reversible inhibitors of SARS-CoV-2 3-chymotrypsin-like protease
por: Li, Dongsheng, et al.
Publicado: (2022)

Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro)
por: Rothan, Hussin A., et al.
Publicado: (2021)

Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection
por: Vandyck, Koen, et al.
Publicado: (2021)

Rutin Is a Low Micromolar Inhibitor of SARS-CoV-2 Main Protease 3CLpro: Implications for Drug Design of Quercetin Analogs
por: Rizzuti, Bruno, et al.
Publicado: (2021)

Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach
por: Gupta, Yash, et al.
Publicado: (2021)

Multistep rational molecular design and combined docking for discovery of novel classes of inhibitors of SARS-CoV-2 main protease 3CLpro
por: Tumskiy, Roman S., et al.
Publicado: (2021)

Dual inhibition of COVID-19 spike glycoprotein and main protease 3CLpro by Withanone from Withania somnifera
por: Patil, Vishal Shivalingappa, et al.
Publicado: (2021)

Loss of chymotrypsin-like protease (CTRL) alters intrapancreatic protease activation but not pancreatitis severity in mice
por: Mosztbacher, Dóra, et al.
Publicado: (2020)

Exploration of chalcones as 3-chymotrypsin-like protease (3CL(pro)) inhibitors of SARS-CoV-2 using computational approaches
por: Lam, Thua-Phong, et al.
Publicado: (2022)

Trypsin- and Chymotrypsin-Like Serine Proteases in Schistosoma mansoni – ‘The Undiscovered Country’
por: Horn, Martin, et al.
Publicado: (2014)

Assessment of activity of chalcone compounds as inhibitors of 3-chymotrypsin like protease (3CL(Pro)) of SARS-CoV-2: in silico study
por: Mathpal, Shalini, et al.
Publicado: (2022)

Structurally- and dynamically-driven allostery of the chymotrypsin-like proteases of SARS, Dengue and Zika viruses
por: Lim, Liangzhong, et al.
Publicado: (2019)

TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19
por: Ansari, Mohammad Azam, et al.
Publicado: (2020)

Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings
por: Lee, Hyun, et al.
Publicado: (2014)

Biochemical screening for SARS-CoV-2 main protease inhibitors
por: Coelho, Camila, et al.
Publicado: (2020)

Molecular Docking Analysis of Anti-Severe Acute Respiratory Syndrome-Coronavirus 2 Ligands against Spike Glycoprotein and the 3-Chymotrypsin-Like Protease
por: Janabi, Ali Hassan Daghir
Publicado: (2021)

In Silico Identification of Potential Inhibitors of the SARS-CoV-2 Main Protease among a PubChem Database of Avian Infectious Bronchitis Virus 3CLPro Inhibitors
por: Soulère, Laurent, et al.
Publicado: (2023)

Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum
por: Gyebi, Gideon A., et al.
Publicado: (2021)

Quaternary Structure of the SARS Coronavirus Main Protease
por: Chang, Gu-Gang
Publicado: (2009)

The Discovery of Small Allosteric and Active Site Inhibitors of the SARS-CoV-2 Main Protease via Structure-Based Virtual Screening and Biological Evaluation
por: Mahgoub, Radwa E., et al.
Publicado: (2022)

Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays
por: Gupta, Yash, et al.
Publicado: (2021)

Treponema denticola chymotrypsin-like protease as associated with HPV-negative oropharyngeal squamous cell carcinoma
por: Kylmä, Anna Kaisa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o944dq91ntfemvvg3ooaecckgd